Refine Results
- Applications and Industries
- Content Type
- Analysis Platform
- Language
- Publication Date
1 - 14 of 14 results
Recently updated Cancer Immunotherapy Handbook featuring the latest high impact xCELLigence publications and newly released supporting information.
Describes use of a tethering approach to immobilize liquid tumor cell lines on to the surface of gold biosensors embedded in an Agilent E-Plate.
In this application note, Antibody Analytics (Motherwell, UK) integrates IndEx-2, an advanced in vitro cell-based platform engineered to modulate the expression of one or two target antigens across a range of biologically relevant levels, with the...
Noninvasive and continuous monitoring of the perturbation of cellular growth following exposure to the cumulative toxicants present in water samples.
To determine if the stimulation of endogenously expressed GPCRs can be monitored by the xCELLigence system, cells were stimulated with various receptor agonists, triggering either Gs-, Gi-, or Gq-mediated downstream signals.
Using the Agilent xCELLigence RTCA system to assess both the selectivity and potency of the TCR-engineered TILs toward HLA restricted cells.
This poster aims to demonstrate the capability of impedancebased xCELLigence RTCA assays for virus and antibody titer, as well as for identification and characterization of antiviral drugs.
There is a need for functional potency assays that can be used to rapidly test the efficacy of different immunotherapy approaches, including but not limited tosmall molecules, biologics, cell therapies, or combinations of these agents
This quick reference guide provides detailed instructions on how to prepare, perform, and evaluate the impedance-based TCID50 protocol using the xCELLigence RTCA Software Pro Virology module to determine viral titer
This editorial showcases Agilent solutions for metabolic modulation enhancing CAR T-cell activation, persistence, and serial killing for improved cancer immunotherapy
SPS 2024. Poster 112-D. To explore the potential on/off target immune-mediated toxicity of EpCAM-CD3 BiTE antibodies, a panel of human primary cells representing different tissues was exposed to EpCAM BiTE in the presence of PBMCs and monitored in...
This editorial will discuss the potency assays available for cellular immunotherapies, the regulatory criteria they must meet, and the challenges faced in measuring immune cell cytotoxicity.
Although cell therapies have shown great promise in clinical studies, challenges with the large scale manufacturing of these therapies still need to be addressed.
Dr. Daniel Hui from Tmunity Therapeutics addresses challenges with cell therapy development with an innovative CAR-T toolbox, using xCELLigence RTCA for measuring potency of immune cell therapies.